InnoCare Pharma Limited: what insiders have been doing
InnoCare Pharma Limited is a listed company. Filings by its managers are published through SSE / SZSE (CSRC). From 8 November 2025 to 8 November 2026, the disclosure feed for InnoCare Pharma Limited logged 4 filings by 3 insiders.
All open-market trades in the period are sales: 4 sales worth €1.4M, by 3 insiders, with no purchase on record. At €755k, the sale published on 17 July 2026 by Jisong Cui(崔霁松) is the largest of the period.
Half of the filings or more reach the SSE / SZSE (CSRC) feed on the day of the trade. This delay matters because a trade only becomes useful information once it is public. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
For context, the typical company on the same exchange (median of 515 companies) published 2 filings over the same period, against 4 filings here. Over the whole record (from 2026), the tally stands at no purchases and 4 sales.
These figures are compiled from regulatory filings published by SSE / SZSE (CSRC). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleThis score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 50,000 shares@ CN¥218.6741100.0% of flowA股XSHGSSE:273000000852817340
- 62,500 shares@ CN¥218.828650.0% of flowA股XSHGSSE:273000000852823680
- 62,500 shares@ CN¥218.684950.0% of flowA股XSHGSSE:273000000845183840
- 206,250 shares@ CN¥218.6741100.0% of flowA股XSHGSSE:273000000845183800
4 of 4 declarations
About InnoCare Pharma Limited
Nuo Cheng Jian Hua is a company focused on the development of innovative drugs, concentrating on research and development of treatments for cancer and other serious diseases.